SCHEMBL4072820

SCHEMBL4072820

COc1ccnc(C(=O)OC(C)(C)C)c1N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 1/20 0.43
ATR Q13535 1/20 0.38
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA3 P34903 1/20 0.37
GABRA6 Q16445 1/20 0.37
APAF1 O14727 2/20 0.36
NSD2 O96028 2/20 0.36
CASP3 P42574 2/20 0.36
SENP8 Q96LD8 2/20 0.36
SENP7 Q9BQF6 2/20 0.36
SENP6 Q9GZR1 2/20 0.36
GRM6 O15303 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM4C Q9H3R0 1/20 0.35
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21855440 0.85 IKBKB (0.46) IKBKBALDH1A1APAF1NSD2CASP3
SCHEMBL6255617 0.84 ATR (0.37) ATRALDH1A1LMNAGABRA1GABRG2
SCHEMBL27483486 0.83 NOS3 (0.43) ATRALDH1A1LMNAGABRA1GABRG2
SCHEMBL28485640 0.82 ATR (0.51) ATRALDH1A1LMNAL3MBTL1CA1
SCHEMBL17980990 0.81 ATR (0.41) ATRALDH1A1LMNAGABRA1GABRG2
SCHEMBL21855442 0.80 IKBKB (0.54) IKBKBALDH1A1APAF1NSD2CASP3
SCHEMBL2003463 0.80 IKBKB (0.47) IKBKBALDH1A1LMNAGABRA1GABRG2
SCHEMBL27510506 0.80 DPP4 (0.47) IKBKBALDH1A1LMNANPC1TDP1
SCHEMBL28027039 0.80 KDM4E (0.42) ATRALDH1A1LMNAGRM6L3MBTL1
SCHEMBL30631987 0.79 NFE2L2 (0.46) ALDH1A1LMNAL3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049490-A1 N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL]-L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS Astra Zeneca AB (SE) 2009-04-22 EP disclosed
US-20080045521-A1 PHENYLALANINE DERIVATIVES ASTRAZENECA AB (SE) 2008-02-21 US disclosed
WO-2007141473-A1 N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL] -L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS ASTRAZENECA AB (SE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045521-A1 PHENYLALANINE DERIVATIVES ITGB5, ITGB1, ITGA2B IKBKB 1838/4885ATR 3216/4885ALDH1A1 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.